Design Therapeutics Q3 2026 Results: Net Loss of $20.3M, Loss Widens
Design Therapeutics reported a net loss of $20.3 million for the third quarter of 2026, driven by $22.2 million in operating expenses primarily for R&D. The company maintained a strong liquidity position with $208.6 million in cash and investments, which management expects will fund operations for at least 12 months.
- Key figure
- Net loss $20.3M